Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data

Fineline Cube Sep 9, 2026
Policy / Regulatory

China Launches Five-Year Plan to Expand High-Quality Eye Health Services

Fineline Cube Sep 9, 2026
Company Drug

Haisco Pharmaceutical’s HSK21542 Accepted for NMPA Review in Postoperative Pain Management

Fineline Cube Oct 19, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...

Policy / Regulatory

NMPA Issues Guidelines for Temporary Import of Urgently Needed Medical Devices

Fineline Cube Oct 19, 2023

The National Medical Products Administration (NMPA) has released new “Management Requirements for Temporary Import and...

Company

Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand

Fineline Cube Oct 19, 2023

Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...

Company Drug

Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial

Fineline Cube Oct 19, 2023

Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...

Company Deals

Eli Lilly Acquires Mablink Bioscience to Expand Next-Gen ADC Portfolio

Fineline Cube Oct 19, 2023

US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink...

Company Deals

Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia

Fineline Cube Oct 18, 2023

Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s...

Company Drug

MicuRx Pharmaceuticals Initiates Phase I Study for MRX-5 in Australia

Fineline Cube Oct 18, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the approval to conduct a Phase I clinical...

Company Drug

GenScript Reports $152 Million in Sales for Carvykti as of September 30, 2023

Fineline Cube Oct 18, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Novartis Launches Leqvio in China at RMB 9,988 per Shot

Fineline Cube Oct 18, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has officially launched its cholesterol-lowering drug, Leqvio (inclisiran), in...

Company Drug

Zhejiang Huahai Pharmaceutical Secures Orphan Drug Designation for HB0034

Fineline Cube Oct 18, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received orphan...

Company Deals R&D

Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development

Fineline Cube Oct 18, 2023

German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based...

Company Medical Device

Lepu Medical Gains NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Oct 18, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Drug

BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC

Fineline Cube Oct 18, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...

Company Deals

Bayer Partners with HALO Precision Diagnostics to Develop Gadoquatrane for MRI Applications

Fineline Cube Oct 18, 2023

Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision...

Company Deals

Hong Kong WinHealth Pharma Enters Strategic Partnership with Nippon Shinyaku for Irsogladine

Fineline Cube Oct 18, 2023

Hong Kong-based WinHealth Pharma Group Ltd has announced a strategic partnership with Nippon Shinyaku Co...

Company Deals

Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies

Fineline Cube Oct 18, 2023

Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...

Company

J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance

Fineline Cube Oct 18, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global...

Company Deals

Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection

Fineline Cube Oct 18, 2023

China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South...

Company Deals

Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology

Fineline Cube Oct 18, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced...

Company Drug

BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer

Fineline Cube Oct 18, 2023

BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed...

Posts pagination

1 … 510 511 512 … 718

Recent updates

  • Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data
  • China Launches Five-Year Plan to Expand High-Quality Eye Health Services
  • Ascletis Starts US Phase 1 Trial of Oral ASC36 for Obesity
  • Baiyunshan Wins Macau Approval for Freeze-Dried Rabies Vaccine
  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data

Policy / Regulatory

China Launches Five-Year Plan to Expand High-Quality Eye Health Services

Company Drug

Ascletis Starts US Phase 1 Trial of Oral ASC36 for Obesity

Company Drug

Baiyunshan Wins Macau Approval for Freeze-Dried Rabies Vaccine

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.